Clearbridge Investments LLC lowered its position in shares of Shire PLC (NASDAQ:SHPG) by 1.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 46,270 shares of the biopharmaceutical company’s stock after selling 446 shares during the period. Clearbridge Investments LLC’s holdings in Shire were worth $7,177,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of SHPG. SeaCrest Wealth Management LLC bought a new stake in Shire during the 4th quarter worth $107,000. Amica Retiree Medical Trust bought a new stake in Shire during the 4th quarter worth $120,000. BB&T Investment Services Inc. grew its position in Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 786 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in Shire during the 3rd quarter worth $159,000. Finally, Benjamin F. Edwards & Company Inc. grew its position in Shire by 277.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 921 shares during the last quarter. Institutional investors and hedge funds own 19.75% of the company’s stock.
A number of brokerages recently weighed in on SHPG. Cowen set a $225.00 price objective on Shire and gave the stock a “buy” rating in a research report on Friday, January 5th. Royal Bank of Canada set a $192.00 price target on Shire and gave the company a “buy” rating in a research report on Monday, February 5th. BidaskClub lowered Shire from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Piper Jaffray Companies reiterated a “hold” rating on shares of Shire in a research report on Wednesday, January 3rd. Finally, B. Riley reduced their price target on Shire from $201.00 to $181.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $204.00.
Shire PLC (NASDAQ:SHPG) opened at $133.45 on Friday. The stock has a market capitalization of $40,660.00, a PE ratio of 21.99, a PEG ratio of 0.77 and a beta of 1.43. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.97 and a quick ratio of 0.55. Shire PLC has a 52 week low of $123.73 and a 52 week high of $192.15.
Shire (NASDAQ:SHPG) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.86 by $0.12. The company had revenue of $4.14 billion for the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.37 earnings per share. sell-side analysts predict that Shire PLC will post 15.23 earnings per share for the current fiscal year.
The firm also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be paid a $0.8937 dividend. This represents a dividend yield of 1.33%. This is an increase from Shire’s previous semiannual dividend of $0.15. The ex-dividend date of this dividend is Thursday, March 8th. Shire’s payout ratio is currently 17.30%.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2018/03/17/clearbridge-investments-llc-trims-position-in-shire-plc-shpg.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.